---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-055100"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:51:44.296999+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma sells remaining Trelegy royalty interest to GSK for $225M

## Summary
- Sells outer-year Trelegy royalties to GSK for $225M cash; transaction closed May 30, 2025.
- Retains right to up to $150M in milestones from Royalty Pharma on 2025/2026 net sales.
- First outcome from Strategic Review Committee formed Nov 2024; board committed to returning excess capital.
- Total potential lifetime value from Trelegy monetization now $1.525B including prior $1.1B upfront.
- 2025 financial guidance unchanged; company continues to focus on YUPELRI and ampreloxetine.

## SEC filing metadata
- accession: 0001104659-25-055100
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465925055100/0001104659-25-055100-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465925055100/tm2516518d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-055100
- JSON: https://secwatch.observer/filing/0001104659-25-055100.json
- Plain text: https://secwatch.observer/filing/0001104659-25-055100.txt

## Key facts
- M&A Transactions
  Theravance Biopharma, Inc. completed a disposition involving GlaxoSmithKline Intellectual Property Development Limited for $225 million (closed 2025-05-30).
  - Action: disposition
  - Counterparty: GlaxoSmithKline Intellectual Property Development Limited
  - Consideration: $225 million
  - Closing: 2025-05-30
  source text: ompany (“TBPH”) and GlaxoSmithKline Intellectual Property Development Limited, a private company limited by shares registered
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465925055100/0001104659-25-055100-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.